Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178687 | 1.00 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29423575 | 1.00 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL13525077 | 0.95 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL3140809 | 0.95 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29792075 | 0.92 | KMT2A (0.90) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29370234 | 0.92 | KMT2A (0.90) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL178801 | 0.92 | KMT2A (0.90) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL18429473 | 0.91 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29587296 | 0.91 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP5FABP7 | |
| Water SCHEMBL21809392 | 0.91 | KMT2A (0.88) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115561372-B | Method for detecting related substances in N-fluorenylmethoxycarbonyl-L-phenylalanine | 重庆莱美隆宇药业有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-113655131-B | Fmoc-Ile-OH related substance detection method | 吉尔多肽生物制药(大连市)有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-115327010-B | Fmoc-L-Pro-OH.H 2 Method for measuring content of O and related impurities | 泰州兴普泰生物制药有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-115561372-A | Method for detecting related substances in N-fluorenylmethoxycarbonyl-L-phenylalanine | 重庆莱美隆宇药业有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-115327010-A | Fmoc-L-Pro-OH.H 2 Method for measuring content of O and related impurities | 泰州兴普泰生物制药有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-115215925-A | Somatostatin type-2 receptor inhibitor and radionuclide complex thereof, and preparation method and application thereof | 上海益泰医药科技有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-112578044-B | Method for detecting Fmoc-AEEA content by high performance liquid chromatography | 成都普康生物科技有限公司 | 2022-09-02 | — | — | CN | claimed |
| US-20260139075-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-3455234-B1 | SECO MACROLIDE COMPOUNDS | SELVITA D O O (HR) | 2026-04-01 | — | — | EP | disclosed |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| EP-3562841-B1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | HOFFMANN LA ROCHE (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-12559573-B2 | Biotin-specific monoclonal antibody and use thereof | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260049101-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | BACOBA AG (CH) | 2026-02-19 | — | — | US | disclosed |
| CN-108350017-B | Polypeptide-labeled nucleotides and their use in nucleic acid sequencing by nanopore detection | 豪夫迈·罗氏有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20220073546-A1 | DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES | BRENTANO BIOTECHNOLOGY ASSOCIATES (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3959224-A1 | B-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION INHIBITING PEPTIDOMIMETICS | University of South Florida (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-114075268-A | Affinity body targeting HER2 and application thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2022-02-22 | — | — | CN | disclosed |
| CN-114053398-A | New medicinal application of heme polypeptide derivative | 吉林省澳宇生物科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3946363-A2 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | Novo Nordisk A/S (DK) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022018264-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, DCLRE1A, PDGFRA | KMT2A 2690/4885EPHX2 3550/4885CASP3 3953/4885 |
| US-12559573-B2 | Biotin-specific monoclonal antibody and use thereof | IGLV6-57, LY96, BTD | KMT2A 829/4885EPHX2 938/4885CASP3 3385/4885 |
| US-20260139075-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | CD22, LY96, F13B | KMT2A 1552/4885EPHX2 2192/4885CASP3 4484/4885 |
| US-20220073546-A1 | DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES | NCL, PCNA, DNTT | KMT2A 4040/4885EPHX2 1398/4885CASP3 4875/4885 |
| US-20260049101-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | NGLY1, MC1R, EGFR | KMT2A 3865/4885EPHX2 867/4885CASP3 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.